An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ELOQUENT-3
- Sponsors Bristol-Myers Squibb
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2016 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 26 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.